Sun Pharma gets FDA labeling supplement approval for oxcarbazepine oral suspension
FDA approved a labeling supplement for Sun Pharmaceutical Industries' generic oxcarbazepine oral suspension.
Sun Pharmaceutical Industries had one FDA action recorded this week involving its generic epilepsy drug.
- Sun Pharmaceutical Industries Ltd's oxcarbazepine oral suspension, 300mg/5ml, received approval for a labeling submission under ANDA078734, supplement number 12, with a standard review priority, effective September 2, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.